Techne grabs Bionostics for $104M

Techne ($TECH), a manufacturer of biological research products, has agreed to buy diagnostics outfit Bionostics for $104 million, a deal it expects to close early next year. Bionostics sells control solutions for the development of in vitro diagnostics, and Techne plans to roll the company's offerings into its R&D Systems business. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.